What AgomAb Therapeutics does

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company headquartered in Antwerp, Belgium, that develops disease-modifying therapies for fibro-inflammatory diseases characterized by organ fibrosis and scarring. Founded in 2017 and listed on Nasdaq under ticker AGMB following its February 2026 IPO, the company targets conditions with high unmet medical need — most notably Fibrostenosing Crohn's Disease (FSCD) and Idiopathic Pulmonary Fibrosis (IPF) — for which no approved pharmacological therapies currently exist and where existing standards of care rely heavily on surgical intervention or cause significant side effects.

The company's core technology is built around organ-restricted small molecule chemistry. Its lead candidate, ontunisertib (AGMB-129), is an oral, gastrointestinal-tract-restricted inhibitor of ALK5 (TGF-βR1) that is designed to act locally in the gut and then be rapidly inactivated in the liver to avoid the systemic toxicities (cardiovascular and large-vessel damage) that have historically limited ALK5 inhibitors; it is advancing into a Phase 2b NOV-RA study in FSCD after positive Phase 2a STENOVA data. AGMB-447 applies the same organ-restricted concept via an inhaled lung-restricted ALK5 inhibitor for IPF and is in Phase 1, while AGMB-101 is an HGF/MET receptor agonist antibody for liver cirrhosis that is Phase 1-ready. The portfolio is protected by composition-of-matter patents (including U.S. Patent No. 12,577,230 covering AGMB-447 through at least 2041) and FDA designations including Fast Track for ontunisertib and Orphan Drug Designation for AGMB-447.

AgomAb is pre-revenue and operates a traditional clinical-stage biopharmaceutical business model, financed entirely through equity capital rather than product sales. The company has raised approximately $300 million in private financing from investors including Pfizer, Sanofi, Fidelity, EQT Life Sciences, Pontifax, Andera Partners, and Boehringer Ingelheim Venture Fund, and added approximately $200 million in gross IPO proceeds in February 2026, taking year-end 2025 cash to €116.5 million and extending the runway into the first half of 2029. It operates three locations (Antwerp headquarters, an R&D laboratory in A Coruña, Spain acquired through the 2021 Origo Biopharma deal, and a U.S. subsidiary in Cambridge, MA), and employs between 51 and 100 staff, primarily in clinical development and regulatory affairs. R&D expenses scaled to €48.9 million in FY 2025 (from €39.3 million in FY 2024), producing a net loss of €62.5 million, with commercialization still multiple years away.

Name

AgomAb Therapeutics

Legal name

Agomab Therapeutics NV

Website

https://agomab.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing organ-restricted small molecule and antibody therapies for fibro-inflammatory diseases, principally Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis. Pre-revenue, listed on Nasdaq since February 2026.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals - Fibrosis Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Fibrosis therapeutics
• Organ-restricted inhibitors
• Biopharmaceutical drug development
• ALK5 inhibitors
• Clinical-stage biotechnology

Headquarters

HQ city

Antwerpen

HQ country

Belgium

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Drug Development and Commercialization: AgomAb is a pre-revenue clinical-stage biopharmaceutical company with no approved products. The company generates no revenue and is funded through private financing and its February 2026 IPO. Future revenue will come from commercialization of drug candidates upon regulatory approval.

Go-to-market motion2 records

Marketing channels5 records

Core offering

AgomAb is a clinical-stage biopharmaceutical company developing disease-modifying small-molecule therapies that target fibrosis by modulating the TGF-β (via ALK5) and HGF/MET pathways, delivering candidates locally to the GI tract (Ontunisertib/AGMB-129 for Fibrostenosing Crohn's Disease), lungs (AGMB-447 for Idiopathic Pulmonary Fibrosis), and liver (AGMB-101 for liver cirrhosis). The company funds operations through equity financing and intends to commercialize its products through standard pharmaceutical distribution channels after regulatory approval.

Product overview

Agomab Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of disease-modifying therapies targeting fibro-inflammatory diseases with high unmet medical need. The company's core approach involves targeting the TGF-β pathway via ALK5 inhibition and the HGF/MET pathway. The lead product, ontunisertib (AGMB-129), is an oral GI-restricted ALK5 inhibitor for Fibrostenosing Crohn's Disease in Phase 2a. AGMB-447 is an inhaled lung-restricted ALK5 inhibitor for Idiopathic Pulmonary Fibrosis in Phase 1. AGMB-101 is a MET receptor agonist antibody targeting liver cirrhosis, Phase 1 ready. All candidates utilize organ-restricted delivery approaches to maximize local efficacy while minimizing systemic toxicity.

Differentiator

Problem solved

Functional benefit

Products and services

• Ontunisertib (AGMB-129) Selective and potent oral, gastrointestinal-tract-restricted small molecule inhibitor of ALK5 (TGFβR1) being developed for the treatment of Fibrostenosing Crohn's Disease (FSCD). Designed to act locally in the GI tract, enabling high exposure in target tissue and rapid hepatic inactivation to avoid systemic toxicities associated with systemic TGF-β inhibition. FDA Fast Track Designation granted; Phase 2b NOV-ERA trial in FSCD expected to initiate in the second half of 2026.
• AGMB-447 Inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβR1) being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Designed to achieve high local exposure in lung tissue while being hydrolyzed and substantially inactivated upon systemic absorption to avoid cardiovascular toxicities. FDA Orphan Drug Designation granted in June 2024; U.S. Patent No. 12,577,230 covers composition of matter with protection through at least 2041. Phase 1 interim results in healthy subjects were positive; IPF patient cohort data expected in H2 2026.
• AGMB-101 Hepatocyte Growth Factor (HGF)-mimetic antibody designed to act through agonism of the MET receptor for the treatment of liver cirrhosis. Has demonstrated both antifibrotic and regenerative activity in preclinical models. Phase 1 ready.

Quantifiable outcome

• Phase 2a STENOVA trial completed with 103 FSCD patients showing positive safety signals and pharmacokinetic results supporting gut-restricted profile
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators13 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Pliant Therapeutics: Clinical-stage biopharmaceutical company developing integrin-targeted therapies for fibrotic diseases including IPF (bexotegrast). Direct peer to AgomAb given shared fibrosis focus, similar clinical stage, and small-molecule approach to validated fibrosis pathways.
• FibroGen: Biopharmaceutical company with a long-standing fibrosis franchise, including pamrevlumab (anti-CTGF) historically in development for IPF. Direct peer given shared focus on disease-modifying fibrosis therapeutics and clinical-stage profile.
• Scholar Rock: Clinical-stage biotech developing therapeutics that target growth factor signaling, including TGF-β activation via latent myostatin and related pathways. Direct peer to AgomAb given shared TGF-β pathway focus and similar clinical-stage development model.
• Morphic Holding: Clinical-stage biopharmaceutical company developing oral integrin inhibitors for fibrotic diseases including IPF. Direct peer given shared small-molecule fibrosis approach, clinical-stage status, and IPF indication overlap.

Emerging players

• Blade Therapeutics: Clinical-stage company developing calpain inhibitors for fibrotic diseases, including IPF. Emerging peer with partial overlap in fibrosis mechanisms and indication focus, though targeting a different biological pathway than AgomAb's ALK5 inhibitors.
• Vivace Therapeutics: Clinical-stage oncology and fibrosis company developing small molecules targeting the TGF-β pathway. Emerging peer with meaningful mechanistic overlap to AgomAb's ALK5 program, though primarily focused on oncology applications.

Broad incumbents

• Galapagos NV: European biopharma with a historical fibrosis franchise, including the discontinued ziritaxestat IPF program. Broad incumbent peer given shared European roots, fibrosis R&D history, and prior clinical-stage development in IPF. Multiple AgomAb executives previously held senior roles at Galapagos.
• United Therapeutics: Established biopharma with Tyvaso (treprostinil) approved for pulmonary hypertension associated with interstitial lung disease, including IPF. Broad incumbent peer operating in the IPF/pulmonary-fibrosis space, representing the kind of larger commercial-stage competitor AGMB-447 would face at launch.
• Boehringer Ingelheim: Global pharmaceutical company that markets Ofev (nintedanib), the leading approved IPF therapy, and is also an existing venture investor in AgomAb. Broad incumbent that is simultaneously a peer in IPF and a financial backer, creating both a competitive and alignment dimension.
• Roche: Global pharmaceutical company that markets Esbriet (pirfenidone), the other leading approved IPF therapy. Broad incumbent peer representing the second entrenched standard-of-care competitor AGMB-447 would need to displace in IPF.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/agomab-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds5 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AgomAb Therapeutics